Introducing the Sunday Times Tech 100: Life Sciences Part 1

Why It Matters

The surge of life‑science tech firms signals strong investor confidence and a shift toward digital health solutions that could relieve pressure on the NHS and accelerate UK biotech commercialization.

Key Takeaways

• 23% of Tech 100 are life‑science firms.
• Lindus Health raised $80M, 265% revenue growth.
• Scan.com profits with £41M revenue, 200% growth.
• Digital pharmacies Phlo and Evaro scaling prescriptions nationwide.
• HeliosX taps GLP‑1 market, 89% growth, 2M customers.

Pulse Analysis

The prominence of life‑science companies in the Sunday Times Tech 100 reflects a broader transformation of the UK’s innovation landscape. While traditional biotech labs remain essential, the rise of software‑centric firms shows that data, AI and platform economics are now the primary growth drivers. Venture capitalists are allocating larger checks to firms that can aggregate health records, streamline trial logistics or deliver care remotely, a trend highlighted by Lindus Health’s $80 million raise and its 265 percent revenue surge.

Each of the five highlighted firms illustrates a distinct angle on digital health. Scan.com leverages a network of private imaging centres to meet soaring demand as NHS waiting lists swell, turning out‑of‑pocket scans into a profitable model. Phlo and Evaro are building end‑to‑end digital pharmacy ecosystems, expanding prescription volumes and integrating compliance services for niche brands. Meanwhile, HeliosX combines telehealth, in‑house compounding and the booming GLP‑1 weight‑loss market to serve over two million patients across four countries, despite remaining loss‑making. These companies prove that scaling revenue does not always require immediate profitability; strategic market capture can justify early‑stage losses.

The ripple effects extend beyond individual firms. As digital health platforms mature, they promise to alleviate NHS capacity constraints, improve patient access, and generate new data streams for research. The upcoming coverage of life‑science hardware will likely reveal complementary innovations in diagnostics and wearables, further cementing the UK’s position as a hub for health‑tech convergence. For investors and policymakers, the Tech 100 serves as a barometer of where capital, talent and regulatory support are coalescing to shape the next decade of British life sciences.